Vishwas B Sovani

Dr. Vishwas B Sovani

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Indian Journal of Public Health Research & Development
Verified
Journal Article
Open access
DPDhirubhai C Patel
Dhirubhai C Patel
VSVishwas B Sovani
Vishwas B Sovani
PJPatel N J
Patel N J
Aim: To study the safety profile and effectiveness of Anti Snake venom (ASV) in western India Methods: This retrospective study gathered safety, epidemiological and clinical data on 157 snake bite patients admitted at Shri Sainath Hospital, in Dharampur, Gujarat, from July 2022 to February 2023. Results: Majority of the bites occurred between August and November. There were 88 males between 5 and 70 yrs. (mean 39.14 yrs.), 69 females between 2 and 70 years (mean 40.32 yrs.). 6 of these were children ranging from 2 to 12 years.134 were agricultural labourers. 120 cases were analysable. 17 had neurotoxicity and 103 had haemotoxicity. Mean (SD) number of vials used was 10.1(6.2), time to discontinue ASV was 3.0(5.2) hours, and duration of hospital stay was 4.5(2.6) days. Patients bitten by saw scaled vipers were discharged early. In Russel’s Viper bites, number of vials used, was higher if the bite to needle time was less than 6 hours 9 patients suffered 24 adverse events, with two possible cases of anaphylaxis. One case had urticaria, itching and tachycardia as a triad. The remaining were isolated events of mild urticaria, itching, tachycardia, hypotension, cough, rigor. Conclusion: All cases were successfully managed with no fatalities or severe comorbidities. Adverse events were reported in 5.7% cases. Mean of 10.1 vials were needed for control of envenomation, a number much less that national guidelines. The ASV brand used was well tolerated. Patients who were brought late suffered more renal complications

23 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
VSVishwas B Sovani
Vishwas B Sovani
RKRogacien Kana
Rogacien Kana
GLGuedem Nekame Jinette Lorraine
Guedem Nekame Jinette Lorraine
ABAwelsa Benoit
Awelsa Benoit
YAYaoua Z. Aladji
Yaoua Z. Aladji
Snakebite envenomation (SBE) is a major public health issue in sub-Saharan Africa (SSA), particularly in Cameroon. This Phase IV, multicenter, open-label study was conducted from June 2024 to December 2024 to evaluate the safety and efficacy of PANAF-Premium™, a World Health Organization (WHO)-approved polyvalent antivenom that was introduced in Cameroon in 2023, given that prospectively gathered data and studies on this antivenom’s safety in SSA are limited. In total, 130 victims admitted to four district hospitals in North Cameroon with confirmed SBE were included. Data on envenomation syndromes, clinical outcomes, adverse events, and treatment response were recorded. Echis species were responsible for most bites, while clinical syndromes included hemotoxic (68.5%), cytotoxic (30.8%), and neurotoxic (0.8%) presentations. On average, victims required 3.34 vials and 5.55 days for clinical recovery. Early antivenom administration significantly reduced the number of antivenom vials required to manage the symptoms (p = 0.003) and hospital stay (p = 0.049). Seventeen patients experienced mild to moderate adverse events. Two deaths and a case of kidney injury were noted, all unrelated to antivenom use. These study findings indicate the safety and effectiveness of PANAF-Premium™ antivenom, meeting WHO performance targets. The results highlight the importance of timely antivenom administration in treating SBEs.

30 December 2024 in International Journal Of Community Medicine And Public Health
Verified
Journal Article
Open access
PDF file
SASheila Aiyer
Sheila Aiyer
VSVishwas B Sovani
Vishwas B Sovani
Diphtheria cases continue to be reported in India despite the national immunization programme although there has been an age shift to older children and adults in the recent outbreaks. This case study follows 17 patients of diphtheria treated at Sir Sayajirao General Hospital Vadodara between September 2022 and September 2023, their clinicoepidemiological profile and management. There were 4 females and 13 males, ages from 7 months to 11 years. While most cases had pharyngeal disease (grade 1), one case had nasopharyngeal disease (grade 2) and three had diseases for more than 3 days and extending to the neck (grade 3). Albert stain was reported positive in 10 cases and culture was not grown in any. Most cases were unimmunized or partially immunized. Mean duration of hospital stay was 9.3 days, longest being 35 days. Three cases died on day 2,4 and 21. In addition to crystalline penicillin, majority were administered Metronidazole and carnitine. DAT was used in doses of 40000, 60000 or 80000 IU uneventfully. When therapy is started based on clinical findings, adding metronidazole increases the spectrum of coverage and using levocarnitine protects against cardiomyopathy. In our series none of our cases died of cardiomyopathy. DAT was not involved in any of the deaths and was found safe and effective in all the cases. Diphtheria persists in different pockets in India and the only way of controlling it by increasing vaccine coverage.

25 September 2025 in Indian Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
VSVishwas B Sovani
Vishwas B Sovani
Medical Publisher in Delhi, India - IP Innovative Publication Pvt Limited, Medical Journals Publication, Open Access Journals, Print Journals,Indian Journals, Surgery, Microbiology, Anaesthesia, Anatomy Biochemistry Books and Journals, Skills for Employability,Best Journal Publishers-IP Innovative Publication Pvt Limit


15 June 2025 in Indian Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
VSVishwas B Sovani
Vishwas B Sovani
Can promotion of medicines be more humane? - IJPP- Print ISSN No: - 2393-9079 Online ISSN No:- 2393-9087 Article DOI No:- 10.18231/j.ijpp.2025.020, Indian Journal of Pharmacy and Pharmacology-Indian J Pharm Pharmacol